D. Tosi

发表

A phase I trial of antifibronecitin 131I-L19-small immunoprotein (L19-SIP) in solid tumors and lymphoproliferative disease

P. Erba, G. Mariani, A. Fasolo, 2008 .

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

P. Srivastava, A. Marchianò, M. Maio, 2006, Cancer Immunology, Immunotherapy.

Immunotherapy of melanoma.

A. Anichini, G. Parmiani, M. Santinami, 2003, Seminars in cancer biology.

Denosumab for treatment of hypercalcemia of malignancy.

G. Tonini, R. Jain, S. Leboulleux, 2014, The Journal of clinical endocrinology and metabolism.

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

V. Diéras, A. van der Gaast, H. Fontaine, 2014, British Journal of Cancer.

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection

C. Gongora, L. Gianni, K. Homicsko, 2018, British Journal of Cancer.

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.

C. Sessa, C. Catapano, F. Bertoni, 2008, European journal of cancer.

B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.

H. Wildiers, M. Campone, M. Piccart-Gebhart, 2019, Journal of Clinical Oncology.

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

J. Moreaux, R. Beijersbergen, P. Martineau, 2019, Cancer research.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

S. Oudard, G. Gravis, N. Houédé, 2015, BMC Cancer.

Pleura and Peritoneum

M. Pocard, O. Sgarbura, S. Gourgou, 2019 .

Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.

E. Brambilla, C. Verri, D. Conte, 2009, American journal of respiratory and critical care medicine.

Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.

A. Fasolo, L. Gianni, K. Homicsko, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Determining the dose to be injected in the first clinical trials with monoclonal antibodies: not so easy!]

D. Tosi, M. Viala, 2019, Medecine sciences : M/S.

A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases.

A. Ravaud, S. Oudard, B. Escudier, 2014, Clinical genitourinary cancer.

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001.

J. Krauss, G. Demetri, R. Doebele, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination

D. Tosi, A. Evrard, M. Viala, 2021, Journal of clinical pharmacy and therapeutics.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

A. Drilon, J. Krauss, G. Demetri, 2019, The Lancet. Oncology.

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.

F. Rojo, J. Albanell, F. Haluska, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)

B. Chauffert, S. Culine, R. Janssen, 2019, Annals of Oncology.

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.

J. Krauss, R. Doebele, J. Wolf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer

B. Győrffy, C. Tacchetti, M. Dugo, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)

M. Piccart, H. Wildiers, G. Curigliano, 2021, Annals of Oncology.

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

A. Italiano, M. Millward, M. Tanner, 2021, Cancer Immunology, Immunotherapy.

Optimal biological dose: a systematic review in cancer phase I clinical trials

C. Bellera, D. Dinart, D. Tosi, 2021, BMC cancer.

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

A. Tolcher, A. Italiano, M. Tanner, 2020, Clinical and translational science.

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.

R. Plummer, M. Toulmonde, A. Italiano, 2018, European journal of cancer.

Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens1

F. Belardelli, G. Parmiani, L. Rivoltini, 2004, The Journal of Immunology.

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001.

J. Krauss, R. Doebele, L. Paz-Ares, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

N. Vié, P. Martineau, M. Del Rio, 2018, BMC Cancer.

347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

M. Piccart, H. Wildiers, P. Tassone, 2020 .

Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.

R. Dziadziuszko, A. Italiano, S. Evers, 2021 .

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

E. Lam, L. Linares, V. Denis, 2016, British Journal of Cancer.

Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.

C. Bourgier, M. Jarlier, A. Pèlegrin, 2020, International journal of radiation oncology, biology, physics.

1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline

A. Drilon, M. Ahn, R. Doebele, 2020 .

543P Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

A. Drilon, J. Krauss, R. Doebele, 2020 .

An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response.

S. Culine, S. Oudard, G. Gravis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in HCT116 colon cancer cells

C. Gongora, L. Bréhélin, D. Tosi, 2023, bioRxiv.

Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.

A. Drilon, A. Shaw, M. Ahn, 2019, Journal of Clinical Oncology.

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients

S. Culine, V. Brouste, P. Pourquier, 2015, Journal of Negative Results in BioMedicine.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.

C. Porta, A. Ravaud, V. Flamand, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer.

F. Bertucci, S. Chevret, I. Ray-Coquard, 2022, Journal of Clinical Oncology.

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models

P. Colombo, N. Radosevic-Robin, N. Vié, 2021, mAbs.

Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis

C. Porta, A. Ravaud, V. Flamand, 2015 .

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

N. Vié, P. Martineau, M. Del Rio, 2018, BMC Cancer.

Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM).

G. Tonini, R. Jain, S. Leboulleux, 2013 .

The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in colon cancer cells

C. Gongora, L. Bréhélin, D. Tosi, 2023, bioRxiv.

Phase 1b study defining the optimal dosing combinations of the mTOR inhibitor AP23573 and Paclitaxel (PTX)

J. Albanell, C. Sessa, L. Gianni, 2007 .

Phase I study with antifibronectin I-131 L19-SIP: First dosimetric and therapeutic results

S. Marsoni, L. Gianni, L. Zardi, 2007 .

Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.

J. Blay, F. Bertucci, S. Chevret, 2023, The Lancet. Oncology.

Pleura and Peritoneum

M. Pocard, O. Sgarbura, S. Gourgou, 2019 .

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

E. Assenat, O. Dereure, K. Klouche, 2023, Journal for ImmunoTherapy of Cancer.

Denosumab for treatment of hypercalcemia of malignancy.

G. Tonini, R. Jain, S. Leboulleux, 2014, The Journal of clinical endocrinology and metabolism.

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.

F. Haluska, L. Gianni, S. Cresta, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—Results of a planned interim analysis.

G. Gravis, F. Joly, P. Barthélémy, 2020 .

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

S. Oudard, G. Gravis, N. Houédé, 2015, BMC Cancer.

Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.

V. Diéras, H. Fontaine, D. Tosi, 2010 .